SP110 and pancreatic adenocarcinoma: For instance, a higher proportion of PAAD patients exhibiting elevated expression of SP100, SP110, or SP140L were observed to have N1 stage disease, indicating a potential connection between increased expression of these family members and disease progression (Figure 2A; Supplementary Table 2).